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Endothelium-dependent vasodilatio of the pulmonary vascular
bed was Investigated in five patients with primary pulmmary
hypertension
. Three endothelium-dependent vasodilators (aeetyl-
choltne, caicttonin gene-related peptide and substance P tin two
patients)) were infused sequentially into the right atrium, followed
by nieurdtpine given orally during full hemodynamic monitoring .
Acetylcholine, caleilonin gerr< re"t :J peptide and substance P
had no effect on pulmonary artery pressure, total pulmonary
vascular resistance or cardiac output, although calcitmin gene-
related peptide significantly decreased systemic arterial systolic
pressure from 132 ± 34 to 113 ± 33 nun Hg. In contrast, oral
Primary pulmonary hypertension is uncommon and its cause
is unknown . It occurs most frequently in women, particu-
larly in the 3rd and 4th decades, and the mean survival time
after symptom onset is only 2 to 3 years (1). Early studies
suggested that arteriolar vasoconstriction was a major com-
ponent of the increased pulmonary artery prcssurc ; a rcim-
lion in pulmonary artery pressure in response to intravenous
aminophylline and tolazoline (2) and intrapulmonary infu-
sion of acerylcholine (3) was reported in patients with
pulmonary hypertension
. One early histopathologic series
(4) showed that in the majority of cases of primary pulmo-
nary hypertension, medial hypertrophy of the small pulmo-
nary arteries and - 'plexogenie" lesions occur and this was
interpreted as evidence for a vasoconstrictioe etiology. The
proposal that the condition was due to pulmonary vasocon-
striction in response to an external stimulus (4,5) prompted
many nonrandomized studies (6-9) using different vasodila-
tor drugs. Unfortunately, treatment with vasodilators has
not been shown to improve survival (9), despite a variable
short-term effect on pulmonary artery pressure and pulmo-
nary vascular resistance (8-10) .
Recently, interest has focused on the pulmonary endo-
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nicardipine decreased tote: pulmonary rascubar resistance from
23 ± 12 to 13 ± 9 U, with, Concomitant hicreene in cardiac output
from 3 .1
t
I to 4.7 t 2 liters,mtat and decrease in systemic
vascular resistance from 38 t 9 to 13 ± 4 ti .
Thus, despite the present : of a reversible component in these
n : patients with primary peetmonarr hypertension, pnlmmary
vascular resistance did rd decrease iin rasp ewe to the ictt-l
:
endothelium-dependent vasodilator agents, indicating that endo.
theltum-dependent vasodilalion is impaired in these patients .
(J Am Coll Caraol 1992
;19:835-41)
thelial cells (11 .12) and it has been proposed that the
plexogenic arteriopatity. which is found in up to 5070 of
cases (13) . may result from endothelial cell injury and this
may affect endothelium-derived mediators of smooth muscle
lone I 11) . It is possible that pan of the increased pulmonary
color
sislance in these patients is due tv impaired
endothelium-dependent vasodilation . This study was de-
signed to investigate the hemnlynamic response of the
pulmonary circulation to the vasoactive agents acelyicholine
(an endothelium-dependent vasodilator and smooth muscle
constrictor 1141) . substance P (an endothelium-dependent
vasodilator [141) and catcitunin gene-related peptide (an
endothelium-dependent and endothelium-independent vaso-
dilator 1151). This response was compared with that after
cumulative oral dosing with the dihydropyridine calcium
channel blocker and smooth muscle dilator nicardipine .
Methods
Study patients (Table 1) . Five consecutive patients with
unexplained pulmonary hypertension were studied . Their
clinical and baseline hemodynamic characteristics are shown
in Table I . A diagnosis of primary pulmonary hypertension
had been made after exclusion of other cardiac and respira-
tory causes of pulmonary hypertension .
All patients were admitted to the coronary care unit and
written consent for the procedures was obtained in each
instance. The protocol was approved by the Research Ethics
Committee of Hamtuc: :.tilh Hospital .
0735-1119719255.00
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Table l . Clinical and HemodynamiA Characteristics of the Five Study Patients
F -Female ;
M =
male : PAP - pulmonary anery pressure : PAWP =
pulmonary artery wedge pressure : P1 - patient : SAP =
systemic arterial press
TPV4 = total pulmonary vascular resistance .
Measurements . A triple-lumen thermodilution catheter
(7F gauge, American Edwards Laboratories) was positioned
in a branch of the right pulmonary artery to allow measure-
ment of right atrial, pulmonary anery and pulmonary artery
capillary wedre pressures . A left radial artery catheter
(Abbocath-T, 20 gauge
; Abbott Laboratories) or right femo-
ral artery catheter (7F gauge
; "ordis UK Ltd.) was inserted
to allow measurement of systemic artery pressure
. Cardiac
output was determined by the indirect Fick method ; oxygen
saturation was measured in samples of pulmonary artery and
systemic arter blood. Total pulmonary vascular resistance
was calculated from the mean pulmonary artery pressure
divided by the cardiac output. Systemic vascular resistance
was calculated from the difference between the mean sys-
temic arterial pressure and mean right atrial pressure and
divided by the cardiac Output . Both total pulmonary and
systemic vascular resistance were expressed as arbitrary
resistance units (dynes's-cm""5 150) . Heart rate was deter-
mined by continuous electrocardiographic monitoring and
pulmonary and systemic arterial pressures were displayed
continuously on a bedside monitor (Marquette Electronics( .
Protocol
. Pulmonary and systemic arterial pressures
were recorded over 60 min to ensure that the bse=
.cline values
were stable . Serial determinations of right atria], pulmonary
and systemic arterial pressures, heart rate and cardiac out-
put were obtained at 5-min intervals
. The administration of
any agent was discontinued if systemic arterial pressure
decreased by >30 mm Hg or if any symptoms developed .
Acetylcholine (Sigma Laboratories) was infused in incre-
mental doses to give estimated pulmonary artery blood
concentrations of 10-9, 10
-1 , 10-1, 10 . 6, 10
s
and 10-4 M .
Each dose was given for 5 min into the right atrium through
the proximal lumen of the catheter. We selected this dosage
regimen because progressive vasodilation occurs in normal
coronary arteries during acetylcholine infusion with esti-
mated blood concentrations of IO -s to IO-6 M (16,17) and
higher concentrations are associated with vasoconstriction
(16) . After a 30-min interval to allow the variables to return
to baseline values, calcitonin gene-related peptide (Sigma
laboratories) was infused a; dos; ;a of 10, 50, 100, 150 and
200 pmo! •min 1 , each dose for 5 minutes, and serial mea-
surements were again determined .
The first two patients studied also received incremental
intracardiac infusions of substance P (Sigma Laboratories),
each dose over 5-min intervals. This was given at doses of
I and 5 pmol-min-I in Patient I and at I, 5 . 10, 15 .20 and 35
pmol-min
-1
in Patient 2. In both patients, marked sympto-
matic flushing and nausea occurred, although there was no
change in systemic or pulmonary artery pressure or cardiac
output. In view of this
. substance P infusions were not given
to the subsequent three patients . One hour after discontinu-
ation of the calcitonin gene-related peptide infusion, patients
received 20 mg of oral nieordipine, every hour
up to a
maximal dose of 200 mg or until systemic arterial pressure
decreased by >30 mm Hg or symptoms developed .
Because of the tendency toward spontaneous hemody-
namie variability in primary pulmonary hypertension
(1S),
we defined a decrease in pulmonary artery pressure of 10%
accompanied by a reduction in total pulmonary vascular
resistance of -30% as a significant response, as previously
suggested by P,devsky el al . (19) .
Statistical analysis. Data were analyzed with use of the
Student paired r test . All values are expressed as mean
values ±i SEM : a value p < 0 .05 was considered statisti-
cally significant.
Results
Acetylcholine (Table 2), Because acetylcholine causes
vasodilation at low doses and vasoconstriction at higher
doses in other vascular beds, we considered only the maxi-
mal decrease in total pulmonary vascular resistance, irre-
spective of the corresponding estimated pulmonary artery
blood concentration, when determining the mean hemody-
namic values. Thus, there was a small maximal decrease in
total pulmonary vascular resistance (19 *_ 5 to 15 ± 5 U, p <
0.05) during infusion of acetylcholine, but in individual
patients, the maximal decrease in total pulmonary vascular
resistance occurred at different estimated pulmonary artery
blood concentrations (10
-
s to 10 -0 M) of acetylcholine (Fig .
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addition- inspection of Figure 1 shows not only that the
decrease in total pulmonary vascular resistance during ace-
lylchohne infusion was small . but also that it was not
dose-related as in the coronary circulation . :he cause of this
variation in pulmonary vascular resistance is uncertain but
may be due to the spontaneous variations in pulmonary
hemodynamics that have been reported in pulmonary hyper-
tension 1181 .
In two of the five patients (Patients 2 and 5). a reduction
in pulmonary artery systolic pressure occurred (82 to 55 and
109 to 95 mm Hg. respectively) . although in the other three
it remained unchanged (Table 2) . Maximal decreases in
systemic vascslar resistance were observed in individual
pal eels again at different estimated pulmonary artery blood
concentrations (10 -1 to W-^ air of acetylcholine (mean
decrease in systemic vascular resistance- 27 *_ 6 to 18
a
5 U,
p < 0.0511 Fig . I). but 0ystemic arterial systolic pressure
decreased only in Patients 2 and 5 (111 to 67 and 142 to
109 mm Hg, respectively).
Cakitonia roe-related peptide (Table 2) . Calcitonin
gene-related peptide did not affect mean total pulmonary
vascular resistance, and only in Patients 3 and 4 was even a
small decrease observed (Fig. 2) . Pulmonary artery systolic
pressure decreased (from 114 to 97 mm Hg) in Patient I .
Although there was a significant reduction in systemic arte-
rial systolic pressure, the decrease in systemic vascular
resisianr a in all five patients did not reach statistical signif-
icance. Hrnvever, systemic vascular resistance decreased
substantially in Patients 3 and 5 (59% and 40% . respectively)
l Fig . 21 .
Substance P. Substance P was given to only two patients
and in both it caused severe Inviting and nausea . Total
pulmonary and systemic vascular resistance and pulmonary
and systemic artery systolic pressure were unchanged in
Patient I after the second incremental dose of 5 pool-min I
and in Patient 2 alter a maximal dose of 35 pmol-min -1 .
Nicardipine (Table 2). Nicardipine significantly reduced
1ota1 pulmonary vascular resistance and increased cardiac
output in all live pationts (Fig . 3) . There was a reduction in
pulmonary artery systolic pressure in Patients I, 3 and 5
(from 101 to 63, 124 to 199 and 130 to 68 mm Hg, respec-
tively(. Systemic arterial systolic pressure and systemic
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Figure 2 . Individual responses of cardiac output
. total pulmonary
vascular resistance and systemic vascular resistance to Increesing
concentrations of calctonin gene-related pepide
vascular resistance were decreased significantly ; despite
thus, nicardipiue v
a
well tolerated
in
this short-term study,
Discussion
We used sequential infusions of aeelylchaline, calcitonin
gene-related peptide and substance P into the tight atrium to
investigate endnlheliu-in
"pr
;Irr' t'asudilution AA the pul-
monary vascular bed in five patients with primary pulinpndry
hypertension . II, vie el the spontaneous hemodynamic
changes that can occur in pulmonary hypertension (18), we
considered significant only those changes in fatal pulmonary
vascular resistance >30% and pulmonary artery pressure
>10% (19).
According to these criteria, this study showed
that acetylcholine and calcitonin gene-related peptide had no
important effects on pulmonary vascular resistance in these
!ACC Vat. 19 . No. 4
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Figure 3. Individual rspon5es vrcardiac Ourput, total pulmonary
vascular tesistace and sustemic ucocatat resistance to cumulative
dosing wilh oral ni-dirine
efiv  patients . Calcitonin gene-related peptide decreased sys-
temic arterial systolic pressure in all patients and systemic
vascular resistance in four . Similarly, substance P had no
effect on pulmonary vascular resistance in the two patients
who received it, although it produced flushing and nausea
. In
contrast . cumulative dosing with oral nicardipiue reduced
total pulmonary vascular resistance and systemic vascular
resistance . These findings indicate that there is a vasocun-
strictive cutapuneet to the increase in pulmonary vascular
resistance in these patients
; this component can be de-
creased by-vasudilatars such as nicardipiue, which net
directly on vascular smooth muscle. bur Foul by endothelium-
dependent vasodiiation .
Nicardipinc is a dihydropyridine calcium antagonist that
reduces contraction of cardiac and vascular smooth muscle
JACC Vol. 19 . No . 4
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cells by competitively inhibiting calcium ion influx through
the slow channel of plasma membranes . It is more selective
for vascular smooth muscle than is nifedipine, diltiazem or
verapamil (20)
. Because of high aqueous solubility, the peak
plasma concentration of nicardipine is reached utter 20 min
to 2 h 121), Systemic bioavailibilty increases with increasing
doses, suggesting satumuan of first-pass metabolism- with
an elimination half-life of approximately I h almost entirely
due to hepatic metabolism 122) . A previous study (22)
indicated that after single oral doses of 10, 20, 30 and 40 mg
.
plasma concentrations of 13 . 32 . 91 and 253 ytg-liter' .
respectively . are achieved (22)
.
Endothelium-dependent vasodilation of the pulmonary cir-
culation . In normal subjects. pulmonary vasodilation occurs
in response to intrapulmonary infusion of acetylcholine (23) .
In one study (23) of 13 patients, infusion of acetylcholine at
a rate of 0.5 mg'min- ' resulted in a decrease in pulmonary
artery pressure, with no change in pulmonary artery wedge
pressure, systemic arterial pressure or cardiac output . This
decrease was greater under hypoxic conditions when there
was increased vascular tone . The mean cardiac output in
that study (23) was 6.53 liters-min' and the estimated
pulmonary artery blood concentration of acetylcholine was
4.3 x 10-7 M . This level is within the range of estimated
pulmonary artery concentrations of acetylcholine at which
we observed decreases in pulmonary vascular resistance,
although it should be noted that the maximal decrease in
pulmonary vascular resistance was only 21 .5% . Similarly, in
another study (24) of patients with pulmonary hypertension
secondary to mitral stenosis . pulmonary artery pressure and
pulmonary vascular resistance decreased in seven of nine
patients studied, unassvciated with any change in cardiac
output after bolus injection of acetylcholine . However, in
secondary pulmonary hypertension, it has been shown (25)
that patients with a higher mean pulmonary artery pressure
(for example- >80 mm Hg) tend not to respond to acetyl-
choline infusion .
There is indirect evidence of a role for endothelium-
derived relaxing factor in the regulation of pulmonary vas
.
cular tone . In the intact rabbit lung preparation in which
vascular tone had been elevated above the baseline and
cyclooxygenase activity blocked, acetylcholine infusion (3 x
10-4 to I x 10-6 M) produced dose-dependent vasodilation
(26) .
Infusion, before and during acetylcholine. of either
quinacrine or hemoglobin (both agents antagonize the
endothelium-derived relaxing !actor-releasing effect of ace-
tylcholine) resulted to further vasoconstriction, implying
endothelium-dependent vasodilation in the pulmonary
vascular bed . Furthermore, in isolated porcine pulmonary
artery rings, this endothelium-dependent vasodilation (in
rings preconstricted by phenylephrine) by acetylcholine
was greater in small (2 to 3 mm) than in large (5 no 7 mm)
arteries (27) . This heterogeneity
i .P,
response may be due to
increased receptor density or enhanced efficiency of recep-
tor coupling . To what degree this endothelium-dependent
vasodilation determines pulmonary vascular tone and put-
939
nonary blvud Row under normal circumstances in not
known.
Endothelial cell dysfunction in pulmonary hypertension .
Abnormalities of endothelial cells in pulmonary hyperten-
sion have been discussed by several groups (28-311. His-
tvlogic evidence of endulhelial cell injury has been shcwa
(28) to occur early before the development of both pulmo-
nary hypertension and increased vascular reactivity (to
hypoxia and epinephrine) after the administration of mono-
crotaline to rats . More than 10 years ago. Sole et al
. IN)
observed that the uptake of norepinephrine by the lungs in
patients with pulmonary hypertension was reduced and
suggested that this reduction was due to endothelial cell
dysfunctiun
. Rabinuviteh et al, (30) also demonstrated in-
tenre immunofiuorescent staining for Yon Willebrand
factor in pulmonary arteriolar endothelium of patients with
pulmonary hypertension secondary to congenital heart dis .
ease and suggested that it is due to altered endothelial cell
metabolism . More recently, Dinh Xuan ct al . (31) showed
impaired endothelium-dependent relaxation in response to
acetylcholine in pulmonary vascular rings obiuined from
patients with pulmonary hypertension secondary to cystic
fibrosis.
Several studies (31-35) have reported vasodilation of the
pulmonary vascular bed in patients with primary pulmonary
hypertension during intravenous infusion of prostacyclin,
which causes vasodilation through a direct action on
smooth muscle cells (36)
.
Prostacyclin is produced by the
pulmonary vascular endothelial cells and because its
infusion causes a decrease in pulmonary vascular resistance
in these patients, it has been proposed that there may
be a deficiency of endothelial prostacyclin production
in some forms of pulmonary hypertension . In one compara-
tive study (34), the calcium channel blocking agent nifedi-
pine given orally was as effective in reducing pulmonary
vascular resistance as was intracardiae prsmcyclin in
the same patients, indicating that the increased pulmonary
vascular resistance was reversible to a similar degree
by two agents with different modes of action on smooth
muscle .
Long-term vasadihfor therapy
. Short-term drug testing
has been widely used as a means of predicting the benefit
from long-term vasodilator therapy in patients with primary
pulmonary h ypertension. an abrupt decrease in pulmonary
artery pressure or pulmonary vascular resistance indicating
a likely long-term effect with subsequent oral vasoddaror
treatment (9,19,34) . The rationale for such testing is that
come patients may have a vasoeoestrtctive component to the
increased pulmonary artery pressure that, if reversible dur-
ing short- term- testing, might benefit from long-term therapy
with drugs such as nifedipme, diltiazem or hydrala2ine
(7-10) . Such an approach may minimize the risk of treating
those patients unlikely to respond (9,37,38) . Because spon-
rancous variations in the pulmonary vascular resistance can
occur in patients with primary pulmonary hypertension, it
was recently suggested (19) that a decrease in pulmonary
840 UREN ET AL.
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vascular resistance should not be considered significant
unless it is
>30% from baseline . If this criterion is used . up
to 50% of
patients whose pulmonary vascular resistance
decreases during acute drug testing may respond to long-
term vasodilmion compared with only 6% of those with a
reduction in pulmonary vascular resistance of <305k
(9) .
Because no randomized controlled long-norm vasodilator
studies have been possibic.long-term treatment with drugs
such as the calcium channel blockers or hydralazine (7,8) in
patients who have had such a short-term decrease in pulmo-
nary vascular resistance has not been shown to improve
survival (7), It has been suggested (39) that the long-term
prognosis relates more to the intrinsic characteristics of the
diseased pulmonary vascular bed than to the treatment
given. It is possible that dilation of all remaining muscular
pulmonary arteries still capable of dilating will help to
preserve function in the lung, prevent deterioration
of the
right ventricle and aid survival in those patients who show a
favorable response.
Conclusions. This study has shown that oral nicardipine
reduced pulmonary vascular resistance in five patients with
primary pulmonary hypertension . indicating that there is a
reversible component . although the magnitude of the re-
sponse was variable. Acetylcholine, calcitonin gene-related
peptide and substance t' (in two patients) did not change
pulmonary vascular resistance, indicating that endothelium-
mediated vasudilation does not occur in the pulmonary
vascular bed in these patients.
We thank Purer L Hammond . MRCP far his assistance in this
.study
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